Use of prostechea karwinskii extract for controlling parameters of the metabolic syndrome

MX439187BActive Publication Date: 2026-10-05NATIONAL POLYTECHNIC INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MX2022007853
Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-06-22
Publication Date
2026-10-05
Estimated Expiration
2042-06-22
Patent Text Reader

Abstract

The present invention relates to developing an extract with anti-metabolic syndrome activity from the leaves, flowers, and pseudobulbs of an endemic Mexican orchid, Prosthechea Karwinskii, selected at a developmental age of no more than eight months, receiving a pre-treatment of washing and lyophilizing, grounding, and extraction by a green chemistry method assisted by ultrasound with a 50% water / ethanol solvent. Said extract was evaluated in Wistar rats with metabolic syndrome induced for 20 weeks with a hypercaloric diet with 40% sucrose in water ad libitum at three concentrations of 100, 200, and 300mg / kg body weight for four weeks, compared with a control group that received a reference drug (metformin), a healthy group, and a group with metabolic syndrome that did not receive the extract. The results show that the extract could reverse the parameters of metabolic syndrome to normal levels with a single extract. In conclusion, the present invention aims to provide knowledge for co ntrolling metabolic syndrome parameters in a single drug, which is a novelty since no treatment worldwide jointly controls hypertension, hyperlipidemia, obesity, pro-inflammatory state, and cardiovascular risk.
Need to check novelty before this filing date? Find Prior Art

Description

USE OF PROSTECHEA KARWINSKII EXTRACT FOR THE CONTROL OF METABOLIC SYNDROME PARAMETERS FIELD OF INVENTION The present invention falls within the biotechnological sector, for the control of parameters associated with metabolic syndrome, specifically it refers to a hydroethanolic extract, and its use in the control of metabolic syndrome, due to its effects: hypoglycemic, hypolipidemic, reducing adipose tissue, protecting against cardiovascular risk, anti-inflammatory and gastroprotective. BACKGROUND OF THE INVENTION Metabolic syndrome is a cluster of obesity-related risk factors that promote the development of type 2 diabetes and cardiovascular disease (Zheng et al., 2020). Individuals with metabolic syndrome are characterized by obesity, dyslipidemia, hyperglycemia, inflammation, and insulin resistance (Dominika et al., 2020; Zheng et al., 2020). Visceral adiposity has been shown to be the main trigger of most of the pathways involved in metabolic syndrome. Of all the proposed mechanisms, insulin resistance and chronic inflammation appear to be the main players in the initiation, progression, and transition of metabolic syndrome to cardiovascular diseases (Rochlani et al., 2017). Insulin resistance in adipose tissue prevents insulin-mediated inhibition of lipolysis, leading to an increase in circulating free fatty acids that further inhibit insulin's anti-lipolytic effect. This also contributes to the development of hypertension due to the loss of insulin's vasodilatory effect and the vasoconstriction caused by free fatty acids. Furthermore, it causes increased serum viscosity, induces a prothrombotic state, and releases pro-inflammatory cytokines from adipose tissue, all of which contribute to an increased risk of cardiovascular disease (Rochlani et al., 2017). Metabolic syndrome is a pro-inflammatory state in which adipose tissue plays a fundamental role in its pathophysiology, as it is considered a biologically active endocrine and paracrine organ. Adipocytes undergo hypertrophy and hyperplasia in response to nutritional excess, which can lead to cells exceeding their blood supply, inducing a hypoxic state. Hypoxia can lead to cell necrosis with macrophage infiltration and the production of adipocytokines, including tumor necrosis factor-alpha (TNF-α). TNF-α is a pro-inflammatory cytokine and an important mediator of numerous cardiovascular pathologies (McCrack et al., 2018). According to the International Diabetes Federation (IDF), it is estimated that by 2025 percent of the world's adult population (more than one billion people) will have metabolic syndrome (Saklayen et al., 2018). These individuals are twice as likely to die, three times as likely to suffer a heart attack or stroke, and have a five times greater risk of developing type 2 diabetes compared to healthy individuals (Stem et al., 2004). According to the World Health Organization (WHO, 2017a), at least 2.8 million people die each year as a result of being overweight or obese; cardiovascular diseases (CVDs) are the number one cause of death worldwide, with an estimated 17.9 million people dying from them in 2016, representing 31% of all deaths globally (WHO, 2017b). The number of people with diabetes has almost quadrupled since 1980; it is estimated that in 2016, 1.Six million deaths were directly caused by diabetes, making it the seventh leading cause of death worldwide (WHO, 2018). Alternative treatments for chronic metabolic diseases are essential due to their impact on population health and their associated effects on public health. Therefore, it is important that insulin resistance and inflammation are considered within the evaluation of metabolic syndrome, since they are the main contributors to the onset, progression and transition of metabolic syndrome to cardiovascular diseases, and allow us a better understanding of the effect of the parameters that are evaluated in a state of metabolic syndrome. Prosthechea karwinskii is an orchid endemic to southern Mexico, growing in pine-oak forests in the states of Michoacán, Guerrero, Mexico, Morelos, Puebla, Veracruz, and Oaxaca. It is a plant with showy yellow flowers, and its ethnomedicinal use includes treating burns, wounds, and coughs. Some of the properties described in the traditional ethnic medicine of P. karwinskii have been described in scientific works, for example, López Pérez et al., (2016), determined the antioxidant capacity in vitro with 1,1 -diphenyl-2-picrylhydrazyl (DPPH) and carried out a phytochemical screening with colorimetric tests to detect the presence of compounds belonging to the families of flavonoids, saponins, tannins, coumarins, cardiotonic glycosides, sesquiterpene lactones, quinones, alkaloids, triterpenoids, anthraquinones, flavones, flavonols, flavanones, aurones, chalcones and xanthones of P. karwinskii extracts obtained by Soxhlet method. The present invention relates to the oral administration of P. karwinskii extract at a dose of 300 mg / kg, which increases adiponectin levels and decreases TNF-α and HSCRP levels. This is equivalent to an anti-obesity effect, a reduction in insulin resistance, a decrease in the pro-inflammatory state, and a reduction in cardiovascular risk in rats with metabolic syndrome induced by a hypercaloric 40% sucrose diet. The main bioactive compounds of the extract are quinic acid, neochlorogenic acid, chlorogenic acid, rutin, kaempferol-3-oP-rutinoside, and embelin. Oral administration of the P. karwinskii extract reduces weight gain, abdominal and pericardial fat deposits, and insulin resistance. At the end of treatment, triglyceride, TNF-α, HSCRP, and adiponectin levels return to near-normal levels. In the state of the art, we find that Silva-Robalino et al. (2019) isolated and identified compounds present in the apolar fraction of the pseudobulbs of P. karwinskii. They performed an in vitro biological evaluation, where the hexane and dichloromethane / methanol extracts showed significant inhibition percentages. In addition to the ability of gigantol and tristine (compounds identified in the extract) to inhibit the growth of cancer cell lines K562 (leukemia), U251 (central nervous system glia), PC-3 (prostate), HCT-15 (colon), MFC-7 (breast), SK.LU (lung), and MES-SA (uterine sarcoma), the bioactivity was not considered relevant as it was less than 50%. The study by Pérez-Gutiérrez & Carlos Hoyo-Vadillo (2011) reports the extraction of chloroform, hexane, and methanol from the orchid Prosthechea michuacana to test their antidiabetic and anti-epidemic activity in an animal model (Wistar rats) of streptozotocin-induced diabetes. Both diabetic and non-diabetic rats received the extract for 28 days. At the end of the study, serum levels of glucose, total cholesterol, triglycerides, and insulin, as well as pancreatic insulin, were evaluated. Only the hexane extract caused a reduction in glucose, total cholesterol, triglyceride, and insulin levels in both diabetic and non-diabetic rats. However, the results obtained only reveal a reduction in glucose levels in a concentration-dependent manner (>400 mg / kg > 200 mg / kg > 100 mg / kg) after the extract was administered. Cervantes Reyes (2008), in his master's thesis, conducted a study on Prosthechea michuacana, an orchid native to Mexico, used in traditional medicine to reduce kidney inflammation and as a circulatory system detoxifier. For this study, extracts were obtained from the rhizome, leaves, and pseudobulbs of the species using hexane, chloroform, and methanol as solvents. Extraction was performed using a Soxhlet extractor, and male Wistar rats were used as the animal model. The anti-inflammatory activity of each extract was evaluated (by induced edema in the rats' ears with TPA), as well as its hypoglycemic activity (in the blood of normoglycemic rats using an enzymatic-colorimetric method) and its wound-healing activity (using a surgical wound made in the thigh of each rat). Leaf extracts-chloroform, rhizome-hexane, pseudobulb-hexane, and pseudobulb-methanol reduced TPA-induced edema in the ear of rats, although in a lower percentage than the positive control (white balm).The rhizome-methanol and pseudobulb-chloroform extracts exhibited similar wound-healing activity to the positive control (Debrisan). The leaf-chloroform, leaf-hexane, and rhizome extracts with chloroform, hexane, and methanol significantly reduced blood glucose levels in mice compared to the negative control (untreated mice). From previous art we can see the need for a single extract from Prosthechea karwinskii that is capable of reversing most or all of the effects of metabolic syndrome with a single extract. In the literature, there is no known treatment that can combat cardiovascular risk, hypertension, hyperglycemia, hypercholesterolemia, obesity, inflammation and gastric damage simultaneously and in composition. Generally, mixtures of drugs with specific activity against some of the effects are made, and in combination they achieve synergy. In the prior art of patent literature, we find WO2021196079A1 and CN109718168 A, which make use of orchid extracts, specifically orchids of the genus Phalaenopsis. This differs from the orchid species used in the present invention, Prosthechea karwinskii, an orchid belonging to another genus and with different physical and chemical characteristics. The part of the plant used in the extracts also differs, as for the patent publication WO2021196079A1 used the embryonic tissue of orchid buds, while patent application CN109718168A uses the entire flowering plant, unlike the present application, which uses the leaves, flowers, and pseudobulbs of the orchid. With respect to the present invention, the difference in orchid species and the plant parts used results in extracts with completely different compounds and properties. In WO2021196079A1, reverse osmosis water is used for extraction, so the extracted compounds are mostly polar compounds, including indole-3-acetic acid; in CN109718168A, the extracted compounds are the volatile fraction, which contains nonpolar compounds such as monoterpenes, including geraniol, sedumol, and their derivatives.The compounds extracted in the present invention using 50% ethanol in water as a solvent include quinic acid, malic acid, succinic acid, (L-(-)-phenylalanine), guanosine, neochlorogenic acid, chlorogenic acid, rutin, kaempferol-3-O-rutinoside, azelaic acid, sebacic acid, N-undecanoylglycine, pinelic acid, and embelin. As can be seen, there are significant differences in the chemical composition of the extracts obtained in the various patents.Regarding the biological properties exhibited by the extracts in those patents, they also differ from those presented in the extract of this application. The extract in WO2021196079A1 exhibits energizing, anti-wrinkle, anti-inflammatory, whitening, antioxidant, anti-aging, protective, and repairing effects; therefore, its use is primarily focused on the development of cosmetic products and medications for skin care. This contrasts with the properties presented in CN109718168A, which are primarily antibacterial, intended for use in cosmetic, food, and pharmaceutical products. The extract of the present invention has properties that reduce obesity, insulin resistance, pro-inflammatory status, and cardiovascular risk associated with metabolic syndrome. It also exhibits properties that reduce reactive oxygen species, which increase during oxidative stress. On the other hand, in the work of Silva-Robalino et al. (2019), unlike the present application, they only evaluated the nonpolar portion of the pseudobulbs of the orchid Prosthechea karwinskii, whose compounds are entirely different from those identified in the extract of the present invention. This difference is also reflected in the biological properties of the extracts, since while the extracts and compounds isolated from the pseudobulbs showed very low activity in the in vitro models evaluated, the extract of the leaves, flowers, and pseudobulbs of the present application showed very good biological activity in the animal model evaluated, which could indicate that most of the bioactive compounds are located in the more polar portion. The difference between the study by Pérez-Gutiérrez & Hoyo-Vadillo (2011) and the present invention lies in the extraction of P. karwinskii plant material using ethanol and water as solvents, instead of environmentally unfriendly solvents (chloroform, hexane, and methanol). The extraction method used in this invention was assisted by green chemistry and ultrasound, which requires less energy and fewer organic solvents. The evaluation of the P. karwinskii extracts was performed on Wistar rats with metabolic syndrome induced by a hypercaloric diet, where diabetes, obesity, insulin resistance, and high cholesterol and triglyceride levels are present.In contrast, in the study by Pérez-Gutiérrez & Hoyo-Vadillo, diabetes was induced by injecting streptozotocin, a toxic antibiotic that, when administered to Wistar rats at a dose of 100 mg / kg, can cause death, and in those that survive, there is a decrease in body weight gain (Bequer et al. 2015, http: / / dx.doi.org / 10.7705 / biomedica.v36i2.2686). Thus, the biological activity of our extract was tested on high levels of glucose, cholesterol, triglycerides, and adipose tissue—all parameters associated with metabolic syndrome and a hypercaloric diet—as a means of evaluating the extract and its potential for addressing one of the major public health problems today. One of the differences between the study by Cervantes Reyes (2008) and the one in this application is the orchid species used. In this application, *P. karwinskii* is used, and ethanol and water were used as solvents instead of environmentally unfriendly solvents (chloroform, hexane, and methanol). The extraction method used for *P. karwinskii* was a green chemistry method (ultrasound), which requires less energy and fewer organic solvents. The evaluation of the *P. karwinskii* extracts was performed on Wistar rats with metabolic syndrome induced by a high-calorie diet, instead of using healthy rats. Thus, the biological activity of the extract was tested on parameters that show levels associated with metabolic syndrome (high concentrations of glucose, cholesterol, triglycerides, and adipose tissue). The hypoglycemic activity of the *P. karwinskii* extract...The anti-inflammatory activity of P. karwinskii was assessed by quantifying the blood glucose concentration of rats previously subjected to a hypercaloric diet, rather than using an enzymatic-colorimetric reaction to estimate glucose concentration in healthy rats. The anti-inflammatory activity of P. karwinskii was evaluated at the level of internal organs using pro-inflammatory markers, such as tumor necrosis factor alpha (TNF-α), in rat liver tissue after administration of the extract, instead of by assessing external (acute) inflammation such as ear edema. Additionally, the background information includes Barragan-Zarate et al. (2020), regarding an extract from P. karwinskii leaves, which were dried in a convection oven. This differs from the leaves used in this application, which were selected according to their size to ensure a higher concentration of bioactive compounds and then lyophilized to remove moisture without affecting the compounds present in the leaves. Although both extracts were obtained using ultrasound, the extract in this application underwent a second extraction to better utilize the compounds not extracted in the first. Once obtained, the extract in this application was subjected to lyophilization to remove the solvent and prevent degradation of the compounds present in the extract, unlike the extract obtained by Barragan-Zarate et al.(2020), which was dried in a fume hood for a longer period, which could affect the compounds present in the extract. Regarding the biological activity tested for each extract, Barragan-Zarate et al. (2020) evaluated the extract's ability to reduce acute inflammation in a carrageenan-induced rat paw edema model, while the activity tested for the extract in this application was to reduce obesity, insulin resistance, pro-inflammatory state, and cardiovascular risk in a sucrose-induced metabolic syndrome model. Although both extracts exhibit anti-inflammatory activity, the acute anti-inflammatory activity evaluated by Barragan-Zarate et al., (2020) corresponds to an immediate response to trauma (injection with carrageenan), while the inflammation tested for the extract of the present application corresponds to a chronic inflammation present during metabolic syndrome, which is a continuous response to said condition, the difference can be noted in the levels of TNF-α (pro-inflammatory cytokine), which did not undergo any change in the evaluation of Barragan-Zarate et al., (2020), while in the present invention, the levels were increased in the rats with metabolic syndrome, while in the rats to which the extract was administered, their levels were regularized. On the other hand, in the work of Rojas-Olivos et al. (2017), the effect of hydroethanolic extracts of leaves, flowers, and pseudobulbs obtained by maceration was evaluated. To extract the compounds, the plant was macerated with 50% ethanol in water as a solvent at room temperature for 7 days, but without the application of ultrasound. In contrast, the extract in this application uses ultrasound to facilitate the extraction of the plant compounds at a temperature of 40 °C, which allows for better extraction without degrading them. Since the extract is obtained using different extraction methods, changes in its composition are expected, and therefore its biological properties will differ. Regarding the biological evaluation, Rojas-Olivos et al., (2017) used a model to induce metabolic syndrome in 13 weeks, while the one in the present application is 20 weeks, and components of metabolic syndrome not covered by Rojas-Olivos et al., (2017) were evaluated. In this application, the effect of the P. karwinskii extract was verified by evaluating parameters of the metabolic syndrome in a broader way, which allowed a more complete understanding of the effect of the extract on metabolic syndrome, encompassing obesity, insulin resistance, pro-inflammatory state and cardiovascular risk. BRIEF DESCRIPTION OF THE FIGURES Figure 1. Raw material, and separation into flowers, leaves and pseudobulbs. Figure 2. Conditioning of the flowers for the extraction of their compounds. Figure 3. Conditioning of the leaves for the extraction of their compounds. Figure 4. Conditioning of the pseudobulbs for the extraction of their compounds. Figure 5. Diagram of the ultrasound extraction process of flowers, leaves and pseudobulbs of Prosthechea karwinskii. Figure 6. Weekly weight records during a) week 1, b) week 2, c) week 3, and d) week 4 of the experimental diet. Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Group with Metabolic Syndrome, MS100=Group with Metabolic Syndrome and P. karwinskii leaf extract at a dose of 100 mg / kg po, MS200=Group with Metabolic Syndrome and P. karwinskii leaf extract at a dose of 200 mg / kg po, MS300=Group with Metabolic Syndrome Metabolic and P. karwinskii leaf extract at a dose of 300 mg / kg po, MSviET=Group with Metabolic Syndrome and metformin at a dose of 200 mg / kg po Figure 7. Effect of Prosthechea karwinskii leaf extract on TNF-α levels, a) in liver tissue and b) in serum. Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Metabolic Syndrome group, MS100=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 100 mg / kg post-mortem, MS200=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 200 mg / kg post-mortem, MS300=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 300 mg / kg post-mortem, MSMET=Metabolic Syndrome group and metformin at a dose of 200 mg / kg post-mortem Figure 8. Effect of Prosthechea karwinskii leaf extract on HS-CRP levels, a) in liver tissue and b) in serum. Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Metabolic Syndrome group, MSioo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 100 mg / kg post-mortem, MS2oo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 200 mg / kg post-mortem, MS3oo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 300 mg / kg post-mortem, MSwET=Metabolic Syndrome group and metformin at a dose of 200 mg / kg post-mortem Figure 9. Effect of Prosthechea karwinskii leaf extract on adiponectin levels. Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Metabolic Syndrome group, MSioo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 100 mg / kg post-mortem, MS2oo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 200 mg / kg post-mortem, MS3oo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 300 mg / kg post-mortem, MSMET=Metabolic Syndrome group and metformin at a dose of 200 mg / kg post-mortem Figure 10. UPLC-ESI-qTOF-MS / MS chromatogram of the leaf extract of Prosthechea karwinskii. Quinic acid (1), Malic acid (2), Succinic acid (3), L-(-)-Phenylalanine (4), Guanosine (5), Neochlorogenic acid (6), Chlorogenic acid (7), Rutin (8), Kaempferol-3-O-rutinoside (9), Azelaic acid (10), Sebacic acid (11), N-Undecanoylglycine (12), Pinelic acid (13), embelin (14). DETAILED DESCRIPTION OF THE INVENTION Due to the multifactorial nature of the disease, its clinical management is difficult, and there is no single treatment that addresses it completely. Common treatment for metabolic syndrome includes weight loss, exercise, a healthy diet, and smoking cessation; however, many patients with metabolic syndrome also require pharmacological treatment, as lifestyle changes alone do not control cardiovascular risk factors. Therefore, medications are used to treat the individual components of metabolic syndrome presented by each patient. Although various studies have been conducted on different treatments for metabolic syndrome, to date, there is no commercially available medication capable of treating it comprehensively. The technical problem to be solved is the development of a single treatment that can address all the health problems associated with metabolic syndrome. Currently, a cocktail of drugs or treatments is used worldwide, each specifically targeting one of the parameters encompassing the problems that develop during metabolic syndrome. These parameters include high glucose, cholesterol, and triglyceride levels, obesity, insulin resistance, a pro-inflammatory state, and cardiovascular risk. The development of an extract with an anti-metabolic syndrome effect would allow for the treatment of all these metabolic syndrome parameters in a single therapy. The invention consists of a hydroethanolic extract of Prosthechea karwinskii and its use in the control of parameters associated with metabolic syndrome. The process for obtaining the hydroethanolic extract is as follows: 1. Conditioning of raw materials The leaves, flowers, and pseudobulbs of Prosthechea karwinskii are selected at a mature stage, just before flowering (6 to 8 months), but not senescent. Knowing that Prosthechea karwinskii has a sympodial growth habit, it consists of a chain of pseudobulbs, each with leaves and an inflorescence that together form a unit. Each unit is produced annually from a new shoot bud that begins its development before the rainy season; before winter, the new pseudobulb and its leaves are fully formed and spend this season dormant. At the end of winter, the inflorescence begins to develop, and flowering takes place in spring; each unit of the sympod (plant) flowers only once.For example, in the case of plant material from Zaachila (Oaxaca) collected during Holy Week (spring), the material consists of individual pseudobulbs with their leaves and inflorescence. These structures, as a unit, developed between the previous rainy season and the spring in which they were collected. Thus, the foliar material used to make the evaluated extract is recently formed on the plants, having developed during the plant's last growing season, a few months prior, from 6 to less than 3 months before its collection in Zaachila. The plant is separated into flowers, leaves, and 8-month-old pseudobulbs, as shown in Figure 1. The different parts of the plant are prepared for the extraction of their bioactive compounds. Once the plant is separated into flowers, leaves, and pseudobulbs, the samples are conditioned for extraction. The preparation method prior to extraction was freeze-drying (lyophilization) to preserve the original chemical composition of the plant species. The flowers are washed with water only to remove any dirt, and then freeze-dried for one week at a vacuum pressure of 73 cmHg (samples no smaller than 25 microns) to remove moisture without compromising their original properties. Once dehydrated, the flowers are ground and sieved through a No. 10 sieve (2 mm) to obtain a fine powder, as shown in Figure 2. In the case of the leaves, they are also washed with water only to remove any dirt, and then freeze-dried for two weeks at a vacuum pressure of 73 cmHg to remove any moisture without compromising their original properties. Once dehydrated, the leaves are ground and sieved through a No. 10 sieve (2 mm) until a fine powder is obtained, as shown in Figure 3. The pseudobulbs are washed with water only to remove any dirt, then sliced ​​into 2-3 mm thick sheets to facilitate dehydration. They are then freeze-dried for three weeks at a vacuum pressure of 73 cmHg to remove moisture without compromising their original properties. Once dehydrated, the pseudobulbs are ground and sieved through a No. 10 (2 mm) sieve to obtain a fine powder, as shown in Figure 4. 2. Ultrasound extraction Extracts of flowers, leaves and / or pseudobulbs of Prosthechea karwinskii are obtained with an ultrasonic probe under the same conditions, regardless of the part of the plant used for extraction. Figure 5 outlines the extraction process using a diagram, which consists of: A) Place the powdered sample in a suitable container for extraction. The sample can be from flowers, leaves, or pseudobulbs of Prosthechea karwinskii. B) Addition of the solvent to the sample, the solvent used is 50% ethanol in water, with a sample: solvent ratio of 1:18 g / mL, that is, for every gram of sample, 18 mL of solvent will be added. The parameters under which the ultrasonic extraction equipment operates are as follows: a power of 750 W, with a frequency of 20 kHz, and an amplitude of 30%. The conditions under which the extract is obtained are: an extraction temperature of 40 °C to avoid the degradation of the thermosensitive compounds, the extraction time is 20 min of work, with programmed pulses of 5 s on and 5 s off to avoid damage to the product. Once the extraction is complete, the extract is filtered to separate it from the plant material. The plant material is then washed again under the same extraction conditions to extract any compounds that could not be extracted during the first extraction. Once the extract is obtained, it is vacuum filtered and the solvent is removed by lyophilization for three days at a vacuum pressure of 73 cmHg. Once the extract is dehydrated, it is placed in an airtight container and stored in the freezer until needed. Evaluation-application To demonstrate the anti-metabolic syndrome activity, the effects of different concentrations of the extract were evaluated: Thirty 21-day-old male Wistar rats were acquired and maintained at 23 °C with a 12-h light / dark cycle, and with access to water and a standard ad libitum diet. Before each experiment, the rats were placed in individual cages with wire mesh floors and fasted for 18 h prior to the experiment; they were given free access to tap water during the fast. Rat management was conducted in accordance with the Mexican Official Standard for the Care and Handling of Animals NOM-062-ZOO-1999 (SAGARPA, 2001) and international rules and standards for the care and use of laboratory animals. For the experimental diet, the animals were divided into two experimental groups: the control group (CG, n=5), fed a standard solid diet (Lab Diet 2018S 18% Protein Rodent, Harían Teklad Inc.) and water; the metabolic syndrome group (MS, n=25) was fed the same standard solid diet and water with 40% sucrose for 20 weeks to induce metabolic syndrome. After week 20, the MS group (n=25) was divided into 5 groups, and the rats continued to be fed a standard diet and water containing 40% sucrose ad libitum. For four weeks, the groups received oral treatment via an esophageal cannula. Each group received the following treatment: Group MS (n=5) received only the aforementioned diet; Group MSioo (n=5) received a dose of 100 mg / kg po of P. karwinskii leaf extract; Group MS200 (n=5) received a dose of 200 mg / kg po of P. karwinskii leaf extract; Group MS300 (n=5) received a dose of 300 mg / kg po of P. karwinskii leaf extract; and Group MSmu (n=5) received 200 mg / kg po of metformin. These groups were compared with the Control Group (CG, n=5), which was fed a standard diet and water.The rats in each group received the treatment orally through an esophageal cannula for four weeks and their weight was recorded weekly. The graphs in Figure 6 show the effect of P. karwinskii leaf extract on rat weight during the experimental diet period. There were significant weight differences between the groups that consumed 40% sucrose and the control group during the four weeks of treatment. Only the rats in groups MS300 and MSmet showed a significantly different weight compared to those that received another dose of P. karwinskii extract, but these differences only occurred in the last week of treatment. At the end of the experiment, the rats were fasted for 18 hours and then sacrificed. The abdominal and pericardial fat deposits of each rat were weighed, and blood was collected, centrifuged at 1086 g for 10 minutes, and the serum sample was stored at -20°C until analysis. Table 1 shows a comparative view of the weight and abdominal and pericardial fat deposits in the rats at the end of the experiment. The hypercaloric diet increased the rats' weight, but this increase was comparatively smaller in the MS300 and MSmet groups. Regarding abdominal fat gain, the extract administration resulted in less abdominal fat gain compared to the MS group, and this gain was dose-dependent, with the MS300 group showing the least gain. As for pericardial fat, the extract reduced its gain in a dose-dependent manner; in this case, the MSjoo group also showed the greatest reduction. This indicates that the extract reduced body weight gain, as well as abdominal and pericardial fat gain, in rats with metabolic syndrome.With the present invention, rats in the MS group exhibited obesity characterized by increased weight and abdominal and pericardial fat deposits compared to the CG group. It was observed that the P. karwinskii leaf extract at a dose of 300 mg / kg orally had an effect on obesity, as it was able to decrease both weight gain and the accumulation of abdominal and pericardial fat, even when the rats continued to be fed the hypercaloric diet. Table 1. Effect of Prosthechea karwinskii extract on weight gain and abdominal and pericardial fat deposits in rats CG MS MS100 MS200 MS300 MSmet Weight at the end of the experiment (g) 412137.36a 515±49.29b 519t47.68b 507+58.08b 487+42.89b 489±65.29b Weight gain (CG) respectively. 103l9.5b 107+9.2b 95110.1b 7517.9' 77+8.5' Abdominal fat (g) 10.6811.68a 32.61l1.91b 28.5314.63b 28.4014.18b 26.35.38b 28.9414.18b Gain of abdominal fat with respect to CG (g) 0a 21.9311.2b 17.8512. Γ 17.7212.3' 16.1211.8' 18.2412.5b0 Pericardial fat (g) 0.20± ,03a0.61±0.09b0.64±0.17b0.52±0.09b0.48±0.08b° 0.53±0.09b Fat gain 0a0.41±0.03b0.44±0.07b0.32+0.02° 0.28±0.02° 0.33±0.03° pericardial compared to the CG (g) Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Metabolic Syndrome group, MSioo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 100 mg / kg po, MS2oo=Metabolic Syndrome group and P. kani'inskii leaf extract at a dose of 200 mg / kg po, MSíoo=Metabolic Syndrome group and P. karwinskii leaf extract at a dose of 300 mg / kg po, MSMi?i=Metabolic Syndrome group and metformin at a dose of 200 mg / kg po Total cholesterol and triglyceride concentrations were measured, as well as glucose and insulin levels. The effect of the extract on insulin resistance was evaluated by calculating HOMA-IR using the formula of Matthews et al. (1985). HOMA-IR = [Fasting insulin (pIU / mL) x Fasting glucose (mmol / L)] / 22.5 The values ​​of the biochemical parameters evaluated in the rats are shown in Table 2. All were significantly higher in the MS group compared to the CG group. The extract had a dose-dependent effect in lowering glucose levels to values ​​close to those observed in the CG rats, and there were no significant differences between the MS300, MSmet, and CG groups. There were no significant differences in insulin levels between the groups administered the extract and the control drug (metformin) compared to the CG group. However, the values ​​of the HOMA-IR insulin resistance indicator were significantly lower in the MS300 and MSmci groups compared to MS. This indicates that the extract had an effect on glucose metabolism, reducing insulin resistance.The extract also had a dose-dependent effect on TG levels; in the MS300 and MSmci groups, TG values ​​became similar to those observed in the control group (CG). This indicates that the extract had a hypotriglyceridemic effect. Regarding TC levels, the extract dose administered to the MS100 group showed the greatest reduction compared to the other extract doses and the control drug. Rats in the metabolic syndrome group exhibited insulin resistance, as they had elevated glucose, insulin, and HOMA-IR levels. Administration of the P. karwinskii leaf extract at a dose of 300 mg / kg po was able to reduce insulin resistance by lowering glucose levels and the HOMA-IR index. Rats in the MS group showed elevated TG and TC levels compared to those in the control group (CG). Adiponectin, TNFα, and HS-CRP levels were also determined in the serum sample from each rat, following the manufacturer's instructions. Liver samples were also taken for tumor necrosis factor-alpha (TNF-α) and high-sensitivity C-reactive protein (HS-CRP) determinations, following the manufacturer's instructions. Table 2. Effect of Prosthechea karwinskii extract on biochemical parameters in Wistar rats GLUCOSE INSULIN HOMA-IR TG TC MS 155 ± 19.22b 12.97 + 1.50b 8.93 ± 0.95c 215.33 ± 11.67b 70.33 ±10.49b MS10o 145 ±4.12b 11.38 ± 1.21b 7.33 ± 0.79c 185.33 ±8.02b 49.2 ± 5.07a MS200 138.33 ±23.47b 11.38±0.86b 7.00 ± 0.82c 176±20.28b 51.33±11.58ab MS300 116.5 ± 12.13a 10.32 ±0.72b 5.45 ± 0.75b 103.66 ± 4.02a 63.66±4.10ab MSmet 97.66 ± 8.05a 11.55 ±0.95» 5.01 ± 0.48 b 99.33 + 7.03a 63.25 ± 8.25ab CG 99.5 ± 6.5a 4.61 ± 0.056a 2.04 ± 0.25a 96.0 ± 4.0a 45.66 ± 4.7a Values ​​expressed as mean ± standard deviation (n=5). Different superscripts indicate significant difference *P<0.05. CG=Control group, MS=Group with Metabolic Syndrome, MSioo=Group with Metabolic Syndrome and extract at a dose of 100 mg / kg po, MS2oo=Group with Metabolic Syndrome and extract at a dose of 200 mg / kg po, MS3cio=Group with Metabolic Syndrome and extract at a dose of 300 mg / kg po, MSMii=Group with Metabolic Syndrome and metformin at a dose of 200 mg / kg po, HOMA-IR = Insulin resistance index, TG = Triglycerides, TC = Total Cholesterol. Figure 7 shows the effect of the P. karwinskii leaf extract on TNF-α levels. In liver tissue, the extract had a dose-dependent effect, with groups MS200, MS300, and MSviet restoring TNF-α levels to the values ​​reported by CG. No significant differences were observed between the groups in serum TNF-α levels. Figure 8 shows the HS-CRP levels recorded after the different treatments. In liver tissue, the extract had a dose-dependent effect, where the MS200 group, MSíoo and MSmci restored HS-CRP levels to the values ​​reported by the CG group. Serum values ​​showed no significant differences between the different groups. The pro-inflammatory state characteristic of metabolic syndrome (MS) in the MS group rats was reversed by administering the P. karwinskii extract, as it decreased the levels of the pro-inflammatory markers TNF-α and HS-CRP, and increased adiponectin levels. TNF-α and HS-CRP levels were increased at the organ level, but not systemically, since there were no significant differences in the values ​​of both parameters between the CG and MS groups in serum, although there were differences in liver function. Figure 9 shows the serum adiponectin levels recorded for the different treatments. The extract had a dose-dependent effect; the group administered the 300 mg / kg post-treatment dose increased adiponectin levels to values ​​significantly similar to those observed in the control group. Adiponectin plays a crucial role in lipid metabolism; its decrease increases the synthesis of lipids and free fatty acids (Calle et al., 2012; Ghadge et al., 2018). Its levels are negatively correlated with triglyceride (TG) levels, while they are positively associated with high-density lipoprotein (HDL) levels in plasma (Cnop et al., 2003; Tschritter et al., 2003). Increased levels of high-sensitivity cortisol-reactive protein (HSCRP) are also related to total cholesterol (TC), HDL, and TG (Mirhafez et al., 2016; Yoon et al., 2018). The MS group rats showed decreased adiponectin levels and increased levels of HS-CRP and pericardial fat, indicative of cardiovascular risk. Administration of the P. karwinskii extract restored these levels to normal and reduced pericardial fat deposits. This suggests that the extract was able to reduce the cardiovascular risk present in the MS animals. Metabolic syndrome promotes the development of cardiovascular diseases (Zheng et al., 2020). Adiponectin is secreted by adipocytes and acts in anti-atherogenesis and vasodilation (Srikanthan et al., 2016); therefore, its decrease contributes to cardiovascular diseases (Calle et al., 2012; Ghadge et al., 2018). Low adiponectin levels are a predictor of myocardial infarction (Nakamura et al., 2004; Pischon et al., 2004; Ghadge et al., 2018). Meanwhile, increased HS-CRP is related to several aspects of metabolic syndrome and cardiovascular diseases (Voils et al., 2014; Mirhafez et al., 2016; Yoon et al., 2018), is a predictor of risk for hypertension and cardiovascular events (Ridker et al., 2008); as a CVD risk factor, HS-CRP is as important a predictor as low-density (LDL) and high-density (HDL) lipoproteins and blood pressure (Ridker et al., 2008; Yoon et al., 2018). Pericardial fat is also associated with cardiovascular disease (Shah et al., 2017), as well as with the development of coronary artery disease (Kahl et al., 2016). The increase in this fat has a high prevalence of cardiometabolic risk factors, including dysglycemia, dyslipidemia, hypertension, adiposity-associated inflammation (Shah et al., 2017), increases in body mass index, abdominal circumference, triglycerides and HS-CRP, as well as a decrease in HDL (Joo, 2017). The extract of P. karwinskii had an anti-obesity effect, decreasing insulin resistance, as well as the pro-inflammatory state and cardiovascular risk, by increasing adiponectin levels and decreasing TNF-α and HS-CRP, parameters that are altered in metabolic syndrome. The presence of the extract's bioactive compounds may explain this effect, acting alone or synergistically on the different metabolic syndrome parameters evaluated here. Due to its multiple bioactivity, this extract has the potential to replace the combination of drugs currently used to treat each component of metabolic syndrome separately. Finally, the compounds of the P. karwinskii leaf extract were identified by UPLC-ESI-qTOF-MS / MS to determine the compounds responsible for the biological properties presented by the extract. The UPLC-ESI-qTOF-MS / MS chromatogram of the P. karwinskii leaf extract (Figure 10) shows that the identified compounds were: quinic acid, malic acid, succinic acid, L-(-)-phenylalanine, guanosine, neochlorogenic acid, chlorogenic acid, rutin, K-aempferol-3ο-β-rutinoside, azelaic acid, sebacic acid, n-undecanoylglycine, pinelic acid, and embelin. The anti-metabolic syndrome evaluation was performed on the blood, organs, and combined body samples of Wistar rats with metabolic syndrome induced over 20 weeks on a hypercaloric diet containing 40% sucrose. The results were compared with a group that received the reference drug (metformin), a healthy control group and another group without metabolic syndrome treatment. During a period of four weeks, the effect of the anti-metabolic syndrome extract was evaluated in a group that received treatment with the extract at three concentrations: 100, 200 and 300 mg / kg of body weight.The records include the rats' weekly weight, weekly weight gain over four weeks, and abdominal and pericardial fat deposits. The analyses include the determination of five biochemical parameters in Wistar rats, such as TNF-α levels in liver tissue and serum, HS-CRP levels in liver tissue and serum, and adiponectin levels at the end of the evaluation period. P. karwinskii extract is capable of reversing all parameters of metabolic syndrome to normal levels with a single extract and a typical high-calorie diet, unlike commercially available treatments worldwide, which are a cocktail of medications. The extract also has the advantage of a gastroprotective effect, unlike NSAIDs, which can cause gastric damage.

Claims

1. An extract of Prosthechea karwinskii to reduce the parameters of metabolic syndrome, characterized by being hydroethanolic and derived from flowers, leaves, and developing pseudobulbs no older than 8 months.

2. The extract according to claim 1, characterized in that its composition comprises: quinic acid, malic acid, succinic acid, L-(-)-Phenylalanine, guanosine, neochlorogenic acid, chlorogenic acid, rutin, Kaempferol-3-op-rutinoside, azelaic acid, sebacic acid, n-undecanoylglycine, pinelic acid and cmbelin.

3. The use of Prosthechea karwinskii extract for the development of a pharmaceutical form useful in reducing the parameters of metabolic syndrome.

4. The use in accordance with claim 2, wherein the extract or pharmaceutical form comprises a concentration of 100, 200 and 300 mg / kg of body weight.

5. Use in accordance with claim 2, wherein the extract or pharmaceutical form is a canary yellow powder, with a particle size of sieve number 10 (2 mm) and is soluble in water under ambient conditions.

6. Use in accordance with claim 2, wherein the extract or pharmaceutical form is administered orally or topically.

7. The use of the extract in accordance with claim 2, to reduce weight, abdominal and pericardial fat deposits.

8. The use of the extract in accordance with claim 2, to decrease insulin resistance.

9. The use of the extract in accordance with claim 2, to decrease levels of triglycerides, TNF-α, HS-CRP (c reactive protein) and adiponectin.

10. The use of the extract in accordance with claim 2, to reduce the risk of hypertension, hyperlipidemia, obesity, pro-inflammatory state and gastroprotective cardiovascular effects.

11. The method for obtaining the extract of claim 1, characterized in that it comprises the following steps: a. Conditioning of the raw material: selecting the raw material from: leaves, flowers, and pseudobulbs of P. Karwinskii, at a mature stage, just in bloom, between 6 and 8 months old and not senescent; washing the leaves, flowers, and pseudobulbs with water and subjecting them to a freeze-drying process for one week at a vacuum pressure of 73 cmHg and with a particle size no smaller than 25 microns; once dehydrated, the raw material is ground and sieved with a No. 10 sieve (2 mm) until a fine powder is obtained. b. Ultrasonic Extraction: dissolving the powdered sample with a 50% water-ethanol solvent at a ratio of g / mL, and introducing it into the ultrasonic extraction equipment at a power of 750 W, a frequency of 20 kHz, and an amplitude of 30%.Maintain the extraction temperature at 40°C for 20 minutes, with programmed pulses of 5 seconds on and 5 seconds off. Finally, separate the plant material by filtration, followed by washing under the same extraction conditions, vacuum filter, and remove the solvent by freeze-drying for three days at a vacuum pressure of 73 cmHg. Once dehydrated, place the extract in an airtight container and store it in the freezer until use.

12. Use in accordance with claim 1, wherein the extract can be used in the manufacture of food products such as: soft drinks, beers, concentrate for preparing beverages, cheeses, yogurt, butters, sweets, desserts, candies, gummies, chocolates, jams, cakes and cupcakes.

13. Use in accordance with claim 1, wherein the extract can be used in the manufacture of food supplements in pills, capsules, syrups, chewable tablets, powders and / or ingestible ampoules.

14. The use of extract, in accordance with claim 1, wherein the leaves, flowers and pseudobulbs belong to orchids of the genus Prosthechea.